DeSilva, M. B., Mitchell, P. K., Klein, N. P., Dixon, B. E., Tenforde, M. W., Thompson, M. G., Naleway, A. L., Grannis, S. J., Ong, T. C., Natarajan, K., Reese, S. E., Zerbo, O., Kharbanda, A. B., Patel, P., Stenehjem, E., Raiyani, C., Irving, S. A., Fadel, W. F., Rao, S., Han, J., Reynolds, S., Davis, J. M., Lewis, N., McEvoy, C., Dickerson, M., Dascomb, K., Valvi, N. R., Barron, M. A., Goddard, K., Vazquez-Benitez, G., Grisel, N., Mamawala, M., Embi, P. J., Fireman, B., Essien, I. J., Griggs, E. P., Arndorfer, J., & Gaglani, M. (2023). protection of Two and Three mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized With COVID-19—VISION Network, August 2021 to March 2022. Journal of infectious diseases, 227, 961–969. http://access.bl.uk/ark:/81055/vdc_100184059601.0x000042